Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBx 10017609 proof-of-concept study in moderate to severe COPD
2010-024640-15Phase 2Completed
- Sponsor
- Ranbaxy Laboratories
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing RBx 10017609 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Mar 2011; status: completed.
02
Drugs
RBx 10017609
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2010-024640-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024640-15.